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Summary
The escort protein SCAP transports SREBPs from ER to Golgi where the active domains are released to activate genes
for fatty acid (FA) and cholesterol synthesis. Mice with conditional SCAP deficiency in liver (L-Scap−) manifest marked
reductions in hepatic lipid synthesis. Here, we show that the decreased FA synthesis in liver is balanced by an equal
increase in nonhepatic tissues, primarily adipose tissue. Extrahepatic synthesis of FAs preserves adipose mass, even
when L-Scap− mice consume a fat-free diet. This compensatory response disappears upon fasting, implicating a role for
insulin, the major hormonal activator of FA synthesis. This response is mediated by an insulin-dependent increase in
adipocyte SREBP-1c and its target mRNAs. In epididymal fat of L-Scap− mice, phosphorylated Akt, Glut-4 mRNA, and
glucose uptake are also increased, indicating insulin hypersensitivity. Plasma VLDL triglycerides are dramatically reduced
in L-Scap− mice, underscoring the benefits of synthesizing FAs in fat rather than liver.Introduction
In mammals, the synthesis and storage of fatty acids (FAs) oc-
cur largely in two organs: liver and adipose tissue (for relevant
articles, see McGarry [1998]; Spiegelman and Flier [1996]). The
liver becomes especially prominent when excess carbohydrate
is ingested. The liver converts the carbohydrate carbons into
FAs, esterifies them to form triglycerides, and secretes them
into plasma packaged in very low-density lipoprotein (VLDL).
For storage purposes, the triglycerides are removed from VLDL
in adipose tissue through the action of lipoprotein lipase (LPL).
The released FAs are taken into the adipocyte, where they are
reesterified and stored. After the triglycerides are removed from
VLDL, the lipoprotein shrinks, and eventually it becomes LDL,
which is cleared from the circulation via LDL receptors in liver
and other organs (Brown and Goldstein, 1983). This division of
labor puts a strain on the LDL receptor system. If LDL recep-
tors are reduced for any reason, such as concomitant ingestion
of excess saturated fats and cholesterol, VLDL-derived LDL
accumulates in plasma (Brown and Goldstein, 1983; Horton et
al., 1999; Twisk et al., 2000) and deposits in arteries, thereby
initiating the inflammatory reaction that leads to atherosclerotic
plaques (Ross, 1993).
The conversion of carbohydrates to FAs in hepatocytes is
controlled reciprocally by insulin and glucagon (for review, see
McGarry et al. [1987]). Dietary carbohydrate stimulates the
secretion of insulin into the portal vein, which carries the hor-
mone in high concentrations directly to the liver. To enhance
FA synthesis, insulin activates the gene encoding a membrane
bound transcription factor called sterol regulatory element
binding protein-1c (SREBP-1c) (Foretz et al., 1999; Shimomura
et al., 1999; Kim et al., 1998). A cleaved fragment of SREBP-
1c enters the nucleus, where it activates all of the genes re-
sponsible for converting carbohydrates to FAs and triglycer-CELL METABOLISM : JANUARY 2005 · VOL. 1 · COPYRIGHT © 2005 ELides (Horton et al., 2002). To facilitate storage in adipose tissue,
insulin stimulates adipocytes to increase the activity of LPL and
Glut-4, a glucose transporter that enhances the uptake of glu-
cose, which in turn generates the glycerol backbone of the tri-
glycerides (Czech and Corvera, 1999).
The essential role of hepatic SREBP-1c in this process was
demonstrated in mice with targeted disruptions in the gene en-
coding SREBP-1c (Liang et al., 2002) and in genes encoding
two of the proteins that are necessary in order for the active
fragment of SREBP-1c to enter the nucleus (Matsuda et al.,
2001; Yang et al., 2001). The latter experiments were possible
because SREBP-1c, like the two other members of the SREBP
family, is synthesized as a membrane bound precursor that
must be liberated proteolytically from membranes in order to
activate transcription (Brown and Goldstein, 1999). Newly syn-
thesized SREBP-1c is embedded in membranes of the ER,
where it forms a complex with an escort protein called SREBP
cleavage-activating protein (SCAP). SCAP carries SREBP-1c
to the Golgi apparatus, where the protein is cleaved sequen-
tially by two proteases, designated Site-1 protease (S1P) and
Site-2 protease (S2P) (Goldstein et al., 2002). The second
cleavage liberates the NH2-terminal fragment of SREBP-1c,
which enters the nucleus and activates transcription of genes
encoding acetyl-CoA carboxylase (ACC), FA synthase (FAS),
and other enzymes required for synthesis of FAs and triglycer-
ides (Horton et al., 2002).
The movement of the SCAP/SREBP complex from ER to
Golgi is controlled by a pair of ER retention proteins called
Insig-1 and Insig-2. When sterol levels build up in cells, SCAP
binds to Insigs, and the SCAP/SREBP complex no longer
moves to the Golgi for processing (Yang et al., 2002; Yabe et
al., 2002). The Insig-1 gene is a direct target of SREBP action,
and Insig-1 levels rise when SREBPs enter the nucleus (Yang
et al., 2002; Horton et al., 2003). Hepatocytes express anotherSEVIER INC. DOI:10.1016/j.cmet.2004.11.004 41
A R T I C L EInsig isoform, Insig-2a, which is regulated reciprocally with In-
sig-1. The Insig-2a gene is expressed at highest levels when
insulin levels are low, and its expression falls when insulin rises
(Yabe et al., 2002; Engelking et al., 2004).
Mice with a conditional disruption of the Scap gene in the
liver have a profound reduction in proteolysis of all three
SREBPs (Matsuda et al., 2001). In the basal state, livers of
these mice exhibit reductions in the mRNAs encoding all lipo-
genic enzymes, and these mRNAs fail to rise when insulin rises
after feeding a single high-carbohydrate meal. As a result,
these mice exhibit an 80% reduction in the rates of hepatic FA
synthesis in the basal or insulin-induced state, as demon-
strated by administration of 3H2O in vivo. As expected, the
levels of VLDL triglycerides in plasma are also low. Similar re-
sults were obtained in mice with a conditional disruption of the
S1p gene (Yang et al., 2001). When the Srebp-1c gene was
ablated, the mice showed a significant but less complete
decrease in hepatic FA synthesis, apparently owing to a com-
pensatory upregulation of SREBP-2, another isoform of SREBP
that can partially substitute for SREBP-1c when overexpressed
in liver (Horton et al., 1998). Mice deficient in SCAP or S1P
have a more severe phenotype because they cannot process
any of the isoforms of SREBP. Overexpression of the ER reten-
tion protein Insig-1 also reduces SREBP processing and lowers
target mRNAs in liver (Engelking et al., 2004; Takaishi et al.,
2004).
The availability of L-Scap− mice allowed us to ask the
following question: what would happen chronically to a mouse
that could not produce normal amounts of FAs in the liver?
Surprisingly, we found that L-Scap− mice appeared normal
(Matsuda et al., 2001) even after being fed for several months
on a fat-free diet. In searching for an explanation, we were sur-
prised to find that adipose tissue took over the function of liver
in converting the excess glucose to FAs. Here, we report the
initial results of these studies.
Results
L-Scap− mice: Conditional deficiency of SCAP in the liver
The L-Scap− mice used in this study have a conditional defi-
ciency of SCAP in the liver and have been previously charac-
terized (Matsuda et al., 2001). These mice were generated by
inserting loxP sites into the 5#-flanking region and intron 1 of
the Scap gene to create a floxed allele. Through selective
breeding, we generated mice that were homozygous for the
floxed Scap allele and heterozygous for a transgene encoding
the Cre recombinase driven by the MX1 promoter, which re-
sponds to interferon (Kuhn et al., 1995). When these mice are
injected four times with a synthetic double-stranded ribonucle-
otide (polyI:polyC), interferon is produced, and Cre recombi-
nase is expressed in the liver, catalyzing recombination be-
tween the loxP sites and inactivating both alleles of the Scap
gene. As a result, hepatic SCAP mRNA and protein levels de-
cline by more than 80% (Matsuda et al., 2001). The SCAP defi-
ciency reduces SREBP processing, and the content of all
nuclear SREBPs declines in livers of the treated animals (Mat-
suda et al., 2001). It is possible that Scap recombines in other
tissues as well (Kuhn et al., 1995), but we did not observe Scap
recombination in adipose tissue (see below). For convenience,
the Scapf/f;MX1-Cre mice are hereafter referred to as L-Scap−
mice to denote the inducible deficiency of SCAP in liver.42Opposite expression of lipogenic mRNAs in liver
and fat of L-Scap− mice
Figure 1A shows relevant mRNA levels in liver (black bars) and
epididymal fat pads (gray bars) of L-Scap− mice, as determined
by quantitative PCR, 17 days after the last of four injections of
polyI:polyC. The mRNA levels are expressed relative to the
mRNA levels measured in age-matched wild-type mice that re-
ceived the same polyI:polyC injections. All of the SREBP-regu-
lated mRNAs declined in liver, as reflected by the downward
direction of the black bars, and rose in adipose tissue, as indi-
cated by the upward gray bars. In liver, the SCAP mRNA was
reduced by about 75%, which reflects the direct action of the
Cre recombinase. Hepatic mRNAs for SREBP-1c, SREBP-2,
and Insig-1, which are direct SREBP targets, declined by more
than 70%, owing to the fall in nuclear SREBPs. SREBP-1a is a
relatively minor mRNA in liver, and its level declined by 50%
with SCAP deficiency. In liver, the mRNAs for all of the enzymes
in FA and cholesterol synthesis declined by more than 75%,
except for stearoyl-CoA desaturase-2 (SCD-2), whose expres-
sion was undetectable.
Strikingly opposite results were observed in the epididymal
fat pads (gray bars in Figure 1A). Here, the mRNAs for all of
the targets of SREBP-1c increased by 2.5- to 12.4-fold. These
targets include the mRNA for SREBP-1c itself, Insig-1, and all
of the enzymes of FA synthesis. The mRNAs for SREBP-1a and
SREBP-2 increased only slightly. The mRNAs for the cholester-
ologenic enzymes HMG CoA synthase and HMG CoA reduc-
tase, which are more responsive to SREBP-2 than SREBP-1c,
failed to increase in the fat pads of L-Scap− mice. The right
side of Figure 1A shows mRNA levels for genes in the insulin
signaling pathway. The only mRNA that showed a significant
change was that for Glut-4, a target of insulin signaling; it
increased 2.5-fold in the fat pads of L-Scap− mice. The mRNAs
for three adipocyte-derived secretory proteins—leptin, adipo-
nectin, and resistin—did not change. We note that the SCAP
mRNA did not decline in white adipose tissue of the L-Scap−
mice, indicating that significant Cre-mediated recombination
did not occur in this tissue (Figure 1A).
Figure 1B shows the time course of changes in mRNA levels
in liver and fat pads at varying times after the last injection of
polyI:polyC in the MX1-Cre mice. The suppression of hepatic
mRNAs had already reached its maximum at the earliest time
point (5 days after the last injection) (triangles in Figure 1B). At
this point, the adipose tissue mRNAs for FA synthesis genes
had not yet begun to rise (circles). The adipose tissue mRNAs
rose progressively over the next few weeks and were still rising
at the last time point, 24 days after the last injection. These
data indicate that the adipocyte response is a delayed reaction
that follows the decrease in the hepatic mRNAs for FA syn-
thesis.
To rule out the possibility that Scap recombination in a non-
hepatic tissue is responsible for the activation of the SREBP
pathway genes in adipose tissue, we created mice homozy-
gous for the floxed Scap allele and hemizygous for a transgene
encoding the Cre recombinase driven by the albumin promoter.
The Cre transgene is expressed almost exclusively in liver
(Postic et al., 1999), in contrast to the MX1-driven Cre
transgene that is expressed in many interferon-responsive tis-
sues (Kuhn et al., 1995). In the Scapf/f;albumin-Cre mice at 15–
17 weeks of age, hepatic mRNA for SCAP was reduced by
54% compared to the wild-type controls. In the liver, this SCAPCELL METABOLISM : JANUARY 2005
Fat metabolism in L-Scap− miceFigure 1. Relative amounts of mRNAs in epididymal fat pads and liver from L-Scap− mice as compared with values in wild-type mice
A) Changes in mRNA levels at 17 days after treatment with polyI:polyC. Male mice (19 weeks, four per group) were injected intraperitoneally four times with polyI:polyC
and then studied 17 days after the last injection. The mice were fed a chow diet ad libitum prior to study. Total RNA from four mouse fat pads (shaded bars) or livers
(filled bars) was pooled and quantified by real-time PCR using primers described in Liang et al. (2002) and in Supplemental Table S1 (see Table S1 in the supplemental
data available with this article online). Each value represents the amount of mRNA in L-Scap– mice relative to that in wild-type mice, which is arbitrarily defined as 1.
For clarity, the scale between 0 and 1.0 is expanded relative to that between 1 and 7. ACL, ATP-citrate lyase; ACS, acetyl-CoA synthetase; ACC, acetyl-CoA
carboxylase; FAS, FA synthase; LCE, long-chain fatty acyl elongase; SCD-1, stearoyl-CoA desaturase-1; IRS, insulin receptor substrate; PEPCK, phosphoenolpyruvate
carboxykinase; Glut, glucose transporter; LPL, lipoprotein lipase; HSL, hormone-sensitive lipase.
B) Changes in mRNA levels at various times after treatment with polyI:polyC. The mice used here are the same as those described in Table 1 and were fed a chow
diet ad libitum prior to study. Total RNA from five mouse livers or five fat pads was pooled and quantified by real-time PCR. Each value represents the amount of
mRNA in L-Scap– mice relative to that in wild-type mice at the same day after the last polyI:polyC treatment.CELL METABOLISM : JANUARY 2005 43
A R T I C L Edeficiency led to a 92% decrease in SREBP-1c mRNA, a 73%
decrease in acetyl-CoA carboxylase (ACC) mRNA, and an 84%
decrease in fatty acid synthase (FAS) mRNA. In the epididymal
fat pads of the Scapf/f;albumin-Cre mice, the mRNA for SCAP
was unchanged, whereas the mRNAs for SREBP-1c, ACC,
FAS, and long-chain fatty acyl elongase (LCE) were increased
by 2.5-, 6.8-, 3.2-, and 6.8-fold, respectively, as compared to
wild-type controls. The degree of Scap recombination in the
livers of the albumin-Cre mice was less than was observed in
the MX1-Cre mice (54% versus 80% reduction in SCAP
mRNA), and the compensatory increase in adipose tissue lipo-
genic mRNAs was somewhat less. Nevertheless, the direction
of the changes in adipose tissue was the same in the albumin-
Cre and MX1-Cre mice, supporting the notion that the changes
in the MX1-Cre mice were secondary to disruption of the Scap
gene in liver and not some other tissue. Inasmuch as the he-
patic SCAP recombination was more efficient in the MX1-Cre
mice and could be induced at will, we used these mice for all
other studies in this paper.
Phenotypic characterization of L-Scap− mice
Table 1 examines various phenotypic parameters of L-Scap−
mice at varying times after the last polyI:polyC injection. At 5
days, the body weights and fat pad weights of L-Scap− mice
were lower than those of the control mice, and the weights in
both sets of mice did not change up to day 24. The hepatic
content of cholesterol and triglycerides was reduced by day 5
in L-Scap− mice and did not change by day 24. Plasma choles-
terol and triglycerides were significantly reduced in L-Scap−
mice and declined further between days 10 and 24. Analysis
of the plasma by FPLC showed that virtually all of the choles-
terol was contained in HDL and all of the triglycerides in VLDL
(data not shown). Plasma-free FAs tended to be lower in
L-Scap− mice. Plasma insulin and glucose were no different in
the two types of mice (Table 1). In other experiments, plasma
leptin levels also did not differ (1.71 and 1.67 ng/ml in wild-
type and L-Scap− mice, respectively).
Quantification of total body fat by total body NMR (Cui et al.,
2004) revealed no significant difference between ad libitum-fed
wild-type and L-Scap− mice when they were examined 14 daysTable 1. Comparison of wild-type and L-Scap− mice at different times after polyI:polyC treatments
5 days 10 days 17 days 24 days
Parameter Wild-type L-Scap− Wild-type L-Scap− Wild-type L-Scap− Wild-type L-Scap−
Body weight (g) 28.8 ± 0.8 25.7 ± 0.6a 27.6 ± 0.7 26.0 ± 0.8 28.5 ± 1.0 26.3 ± 1.1 28.5 ± 1.1 25.5 ± 0.8
Liver weight (g) 1.6 ± 0.1 1.5 ± 0.1 1.4 ± 0.1 1.6 ± 0.1 1.4 ± 0.1 1.6 ± 0.1 1.4 ± 0.1 1.5 ± 0.1
Epididymal fat pad weight (g) 0.23 ± 0.05 0.16 ± 0.02 0.24 ± 0.2 0.17 ± 0.01a 0.18 ± 0.01 0.15 ± 0.03 0.28 ± 0.05 0.15 ± 0.03
Liver cholesterol content (mg/g) 3.0 ± 0.1 2.1 ± 0.1b 2.5 ± 0.0 1.9 ± 0.1b 2.5 ± 0.1 1.8 ± 0.1b 2.4 ± 0.1 1.8 ± 0.0b
Liver triglyceride content (mg/g) 13.9 ± 1.6 1.1 ± 0.3b 9.1 ± 0.9 2.6 ± 0.7b 5.5 ± 1.3 1.4 ± 0.4b 5.5 ± 0.9 1.3 ± 0.4b
Plasma cholesterol (mg/dl) 123 ± 11 43 ± 2b 112 ± 8 61 ± 10 b 109 ± 9 38 ± 3b 97 ± 3 35 ± 5b
Plasma triglycerides (mg/dl) 89 ± 7 55 ± 12a 128 ± 13 57 ± 11b 90 ± 11 33 ± 3b 116 ± 22 28 ± 2b
Plasma FAs (M) 445 ± 75 161 ± 21b 412 ± 43 298 ± 57 362 ± 63 266 ± 15 317 ± 30 237 ± 33
Plasma insulin (ng/ml) 0.91 ± 0.27 1.2 ± 0.36 1.1 ± 0.23 0.95 ± 0.29 1.1 ± 0.36 0.60 ± 0.22 1.3 ± 0.37 1.0 ± 0.32
Blood glucose (mg/dl) 140 ± 8 130 ± 6 132 ± 5 128 ± 8 132 ± 12 113 ± 7 126 ± 8 109 ± 6
Male mice (12–16 weeks, five per group) were injected intraperitoneally four times with polyI:polyC as described in Experimental procedures and subjected to study 5,
10, 17, or 24 days after the last injection. The mice were fed a chow diet ad libitum prior to study. Each value represents the mean ± SEM of five values. Asterisks
denote the level of statistical significance (Student’s t test) between wild-type and L-Scap− mice. Mean body weight before treatment with polyI:polyC was 27.6 g and
26.2 g for wild-type and L-Scap− mice, respectively.
a p < 0.05
b p < 0.0144after the last treatment with poly I:polyC. Values (mean ± SEM)
for total body fat as a percentage of body weight in four wild-
type and four L-Scap− mice were 11.9% ± 1.9% and 10.8% ±
0.6%, respectively (p = 0.59).
Fatty acid synthesis in L-Scap− mice:
Down in liver, up in fat
To determine whether the changes in lipogenic mRNAs were
associated with parallel changes in rates of lipid synthesis in
L-Scap− mice, we administered 3H2O intraperitoneally 31 days
after the final polyI:polyC injection (Figure 2). After 30 min, the
livers and epididymal fat pads were excised and saponified in
order to measure the content of 3H-FAs and 3H-cholesterol.
The fat pad was used as a general indicator of the rate of FA
synthesis in white adipose tissue. The remainder of the car-
cass, including all of the other fat depots, was also saponified
to determine the content of 3H-FAs and 3H-cholesterol in all
other tissues. We killed the animals at 30 min because prelimi-
nary studies showed that the content of 3H-FAs was rising lin-
early at this time point. Half of the mice in this study were main-
tained on a standard chow diet (6% fat), and the remainder
were placed on a fat-free diet 2 days after the last polyI:polyC
injection and maintained on this diet for 29 days. Wild-type and
age-matched L-Scap− mice were studied in the same experi-
ment, and the results are presented graphically in Figure 2.
When expressed on a per gram basis, FA synthesis was re-
duced by more than 80% in livers of L-Scap− mice as com-
pared with wild-type mice when both were fed a chow diet
(black bars in Figure 2A). The fat pad showed the reciprocal
effect: the content of 3H-FAs per gram was 4-fold higher in
L-Scap− adipose tissue than in the wild-type organ (Figure 2A).
Figure 2C presents these results on a per animal basis. In wild-
type mice, the liver incorporated 34 µmol of 3H2O into FAs per
hr, accounting for 34% of total body FA synthesis. In L-Scap−
mice, hepatic incorporation fell to 7 µmol/hr, which accounted
for only 7% of total body synthesis. In L-Scap− mice, the deficit
of 27 µmol/hr in hepatic FA synthesis was compensated pre-
cisely by an increase of 25 µmol/hr in the rate of FA synthesis
in “other tissues.” As a result, there was no overall deficit in
whole-body FA synthesis. This compensation was not seenCELL METABOLISM : JANUARY 2005
Fat metabolism in L-Scap− miceFigure 2. In vivo synthesis rates of FAs and sterols
in different tissues and whole body of wild-type and
L-Scap− mice
Male mice (16–18 weeks, five per group) were
treated with four injections of polyI:polyC as de-
scribed in Experimental procedures. Two days after
the final polyI:polyC injection, two groups of mice
were fed a fat-free diet ad libitum, and two groups
of mice were fed a chow diet ad libitum. Thirty-one
days after the final polyI:polyC injection, each mouse
was injected intraperitoneally with 3H-labeled water
(50 mCi in 0.25 ml of isotonic saline), and 30 min
later the tissues were removed for measurement of
3H-labeled FAs (A and C) and digitonin-precipitable
sterols (B and D). Other tissues refer to the whole
body minus the liver and epididymal fat pads. Each
bar represents the mean ± SEM of values from five
mice. Asterisks denote the level of statistical signifi-
cance (Student’s t test) between the wild-type and
L-Scap− mice. ‡p < 0.05; *p < 0.01.when cholesterol synthesis was measured (Figures 2B and 2D).
The rate of 3H-cholesterol synthesis declined by 82% in livers
of L-Scap− mice, but there was no increased synthesis in the
fat pad or other tissues. As a result, whole-body cholesterol
synthesis was reduced by 43% in the L-Scap− mice (Figure 2D).
In previous studies of L-Scap– mice, it was noted that he-
patic mRNAs encoding FA biosynthetic enzymes failed to
increase to a normal extent when the animals were fasted and
refed (Matsuda et al., 2001). To determine whether the de-
fective FA response would persist chronically, we injected wild-
type and L-Scap− mice with polyI:polyC and then placed them
on a chow diet or a fat-free (high-carbohydrate) diet for 15
days. At this point, the livers were excised, and various mRNA
levels were measured by quantitative PCR (Table 2). On the
chow diet, the results confirmed the markedly lower levels of
mRNAs encoding FA biosynthetic enzymes in L-Scap− mice.
When wild-type mice were placed on the fat-free diet, the
levels of the lipogenic mRNAs increased by 2.2- to 6.4-fold. In
L-Scap− mice, the fat-free diet elicited a similar relative
increase in hepatic mRNA levels, but the absolute levels re-
mained well below normal. It is possible that the partial
increase in the mRNA levels in L-Scap− mice is attributable to
the residual 20%–30% of SCAP mRNA that was not eliminated
by the Cre recombinase (see Discussion).
To determine whether the mRNA response to the fat-free diet
resulted in increased rates of FA synthesis, in the experiment
of Figure 2, we placed half of the mice on a fat-free diet for 29
days prior to killing the animals in the fed state at the end of
the dark cycle (red bars). In livers of wild-type mice, the fat-
free diet elicited a 3-fold increase in FA synthesis so that the
liver now accounted for 54% of total body synthesis. Although
we observed an increase in synthetic rates in fat pads and in
the other tissues, the increase in the liver (65 µmol/hr per ani-
mal) accounted for most of the increase observed in the whole
body (87 µmol/hr per animal). In L-Scap− mice, the fat-free diet
also elicited an increase in hepatic FA synthesis. In relative
terms, this increase was at least as high as in the wild-type
mice, but the absolute rate remained quite low, consistent with
the reduction in mRNAs for FA biosynthetic enzymes. In con-CELL METABOLISM : JANUARY 2005trast to the results in wild-type mice, the other tissues in L-Scap−
mice responded briskly to the fat-free diet so that the whole-
body rate of FA synthesis remained the same in wild-type and
L-Scap− mice.
For completeness, in the experiment of Figure 2, we mea-
sured the rates of [3H]cholesterol synthesis in the animals
placed on a fat-free diet. In the normal animals, this diet pro-
duced a marked fall in rates of hepatic cholesterol synthesis
(compare solid red and black bars in Figures 2B and 2D), con-
sistent with the fall in mRNA levels for the cholesterol biosyn-
thetic enzymes (see Table 2) and a 90% decrease in HMG CoA
reductase protein as determined by immunoblotting (data not
shown).
Increased insulin sensitivity in fat of L-Scap− mice
The fall in plasma triglycerides and free FAs in L-Scap− mice
on a chow diet (Table 1) raised the possibility that insulin sensi-
tivity might be increased. To test this possibility, we performed
a glucose tolerance test (Figure 3A). Eighteen days after the
last polyI:polyC injection, wild-type and L-Scap− mice were in-
jected with glucose intraperitoneally, and blood glucose was
measured at varying time points. At all time points, the glucose
values in L-Scap− mice were lower than those in wild-type
mice. To determine whether the decreased glucose was due to
an increase in plasma insulin, we performed another glucose
tolerance test. At the 30 min time point, we killed the mice so
that sufficient plasma could be obtained to measure insulin
levels. As shown in Figure 3B, the glucose levels in L-Scap− mice
were significantly lower than those in the wild-type mice. How-
ever, the plasma insulin levels were no different in the two types
of mice. Similar findings were observed in another independent
experiment involving five mice in each group. The lower glucose
levels in L-Scap− mice might reflect an increased insulin sensitiv-
ity in these animals. To examine this possibility, we performed an
insulin tolerance test. We injected insulin (0.25 U/kg body weight)
intraperitoneally to ad libitum-fed animals, after which blood sam-
ples were collected over the ensuing 1 hr for glucose measure-
ment (Figure 3C). At 30 and 60 min after injection, the glucose
levels were significantly reduced in the L-Scap− mice, suggesting45
A R T I C L ETable 2. Relative amounts of mRNAs in livers of wild-type and L-Scap− mice fed a chow or fat-free diet
Wild-type L-Scap−
mRNA Chow Fat-free Chow Fat-free
SREBP pathway
SCAP 1 1.3 0.3 0.2
SREBP-1a 1 1.0 0.5 0.9
SREBP-1c 1 1.4 0.02 0.2
SREBP-2 1 0.7 0.3 0.3
Insig-1 1 1.0 0.1 0.1
Insig-2a 1 1.9 0.5 0.6
Insig-2b 1 0.6 1.1 1.6
FA and triglyceride synthesis
ATP-citrate lyase 1 3.2 0.3 0.4
Acetyl-CoA carboxylase 1 3.6 0.2 0.5
Fatty acid synthase 1 6.4 0.04 0.2
Stearoyl-CoA desaturase-1 1 6.2 0.01 0.2
Glycerol-3-phosphate acyltransferase 1 2.2 0.4 0.4
Malic enzyme 1 3.2 0.5 0.3
Cholesterol synthesis and uptake
HMG-CoA synthase 1 0.4 0.1 0.1
HMG-CoA reductase 1 1.2 0.2 0.2
Farnesyl diphosphate synthase 1 1.1 0.03 0.04
Squalene synthase 1 0.5 0.1 0.1
LDL receptor 1 1.2 0.4 0.4
Apoproteins
ApoB 1 1.0 0.9 0.9
ApoE 1 1.1 0.9 0.8
Others
Insulin receptor 1 1.1 0.9 0.8
Insulin receptor substrate 1 1 1.1 0.9 0.9
Insulin receptor substrate 2 1 1.0 0.6 0.6
Phosphoenolpyruvate carboxykinase 1 1.4 1.0 1.2
Male mice (17–19 weeks, four to five per group) were injected intraperitoneally four times with polyI:polyC. Two days after the final injection, mice were fed ad libitum
with either a chow or fat-free diet for 15 days prior to study. Total RNA from four to five livers was pooled and quantified by real-time PCR. Cyclophilin was used as
the invariant control. Values represent the amount of mRNA relative to that in chow-fed wild-type mice, which is arbitrarily defined as 1.the possibility of enhanced insulin action in one or more tissues,
such as adipose tissue or skeletal muscle.
To determine whether L-Scap− mice had an increase in glucose
clearance in one of these tissues, we injected the animals with
[3H]2-deoxyglucose, which can be taken up by glucose transpor-
ters and phosphorylated by hexokinase to [3H]2-deoxyglucose-
6-phosphate but cannot be metabolized further (Hom et al., 1984;
Zisman et al., 2000). After 1 hr, we isolated various tissues and
measured the content of [3H]2-deoxyglucose-6-phosphate as a
measure of total hexose uptake (Figure 3D). Uptake was signifi-
cantly increased in the epididymal fat pads. Uptake also ap-
peared to be increased in skeletal muscle, but this did not
reach statistical significance in the five mice studied.
The finding of enhanced [3H]2-deoxyglucose uptake in the
fat pads of L-Scap− mice suggested that insulin sensitivity
might be increased in this organ. Accordingly, we measured
the level of phosphorylated Akt, a target of the insulin phos-
phorylation cascade (Spiegelman and Flier, 1996), in adipose
tissue of ad libitum-fed wild-type and L-Scap− mice 28 days
after the last polyI:polyC injection (Figure 3E). Densitometric
quantification showed a 3-fold higher level of phosphorylated
Akt in L-Scap− mice as compared to wild-type mice. The level
of total Akt was unchanged. Figure 3F compares the level of
phosphorylated Akt in fat pads, liver, and skeletal muscle 3046min after the mice were injected intraperitoneally with D-glu-
cose. L-Scap− mice showed a 4-fold increase in phosphory-
lated Akt in fat pads but no increase in either liver or skeletal
muscle.
Response to fasting in L-Scap− mice
If the compensatory increase in lipogenic mRNAs in adipose
tissue of SCAP-deficient mice is caused by increased sensitiv-
ity to insulin, these mRNAs should decline markedly when
L-Scap− mice are fasted and insulin levels fall. Accordingly, po-
lyI:polyC-injected wild-type and L-Scap− mice were subjected
to a 12 hr fast, and the results are shown in Table 3 and Figure
4. Fasted L-Scap− mice tended to lose a higher proportion of
body weight than the wild-type mice (21% versus 4% in Table
3 and 24% versus 3% in an independent experiment with three
mice in each group). This difference was reflected in a greater
reduction in the weights of liver and fat pads in L-Scap− mice.
Plasma FAs rose to similar high levels in the fasted wild-type
and L-Scap− mice, but the accumulation of liver triglycerides
was much less in L-Scap− mice. Plasma insulin levels declined
precipitously in both wild-type and L-Scap− mice, and plasma
glucose levels also fell.
In fat pads, the mRNA for SREBP-1c, a direct target of insu-
lin action, declined dramatically upon fasting of L-Scap− miceCELL METABOLISM : JANUARY 2005
Fat metabolism in L-Scap− miceFigure 3. Increase in glucose sensitivity in L-Scap− mice
Male mice (14–18 weeks) were treated with four injections of polyI:polyC as described in Experimental procedures.
A) Glucose tolerance tests in wild-type and L-Scap− mice. Eighteen days after the final polyI:polyC injection, wild-type and L-Scap− mice (seven to eight per group)
were fasted for 16 hr and injected intraperitoneally with 20% D-glucose (2 mg/g body weight). Blood samples (10 l each) were obtained from the tails at the indicated
times for glucose measurement. Each circle represents the mean ± SEM of values from seven or eight mice. Asterisks denote the level of statistical significance
(Student’s t test) between the wild-type and L-Scap− mice. *p < 0.01.
B) Glucose and insulin levels in wild-type and L-Scap− mice (four per group) 30 min after intraperitoneal injection of D-glucose. *p < 0.01.
C) Insulin tolerance tests in wild-type and L-Scap− mice. Twenty days after the final polyI:polyC injection, insulin tolerance tests were performed on nonfasted mice 4
hr after the beginning of light cycle by intraperitoneal injection of human insulin (0.25 U/kg body weight). Blood samples were obtained as described above. Each circle
represents the ± SEM of values from six mice. The “100% of initial” blood glucose values were 117 and 109 mg/dl for wild-type and L-Scap− mice, respectively. #p <
0.02; *p < 0.01.
D) Glucose uptake in various tissues of wild-type and L-Scap− mice. Twenty-four days after the final polyI:polyC injection, wild-type and L-Scap− mice (five per group)
were fasted for 16 hr and injected intraperitoneally with 2-deoxy-D-[1-3H]glucose (0.5 Ci/g body weight) mixed with 20% D-glucose (2 mg/g body weight) to measure
tissue levels of 2-deoxy-D-[1-3H]glucose as described in Experimental procedures. Each bar represents the mean ± SEM of values from five mice. Asterisks denote
the level of statistical significance (Student’s t test) between wild-type and L-Scap− mice. *p < 0.01. Skeletal muscle refers to a mixture of gastrocnemius and
soleus muscles.
E) Immunoblot analyses of Akt and phospho-Akt in fat pads of wild-type and L-Scap− mice on a chow diet. Twenty-eight days after the final polyI:polyC injection,
immunoblot analyses of total Akt and phospho-Akt(Ser 473) (p-Akt) in fat pads of wild-type and L-Scap– mice (three per group) were carried out on ad libitum-fed mice
as described in Experimental procedures. Blood glucose levels (mean ± SEM) were 123 ± 2 and 115 ± 6 mg/dl for wild-type and L-Scap− mice, respectively. Insulin
levels were 0.69 ± 0.15 and 0.66 ± 0.19 ng/ml wild-type and L-Scap− mice, respectively. Filters were exposed to film for 30 s.
F) Immunoblot analyses of Akt and phospho-Akt in fat pads, liver, and skeletal muscle of wild-type and L-Scap− mice 30 min after intraperitoneal injection of
D-glucose. The mice used here are the same as those in (B). Filters were exposed to film for 30 or 60 s as indicated.CELL METABOLISM : JANUARY 2005 47
A R T I C L ETable 3. Effect of fasting on metabolic parameters in wild-type and L-Scap− mice treated with PolyI:PolyC
Wild-type L-Scap−
Parameter Nonfasted Fasted Nonfasted Fasted
Body weight (g) 27.1 ± 0.4 26.2 ± 1.3 26.6 ± 0.7 21.1 ± 1.0a
Liver weight (g) 1.5 ± 0.1 1.2 ± 0.1 1.7 ± 0.1 1.1 ± 0.1
Epididymal fat pad weight (g) 0.23 ± 0.01 0.21 ± 0.03 0.15 ± 0.03 0.09 ± 0.01a
Liver cholesterol content (mg/g) 2.1 ± 0.1 2.7 ± 0.1 1.6 ± 0.1b 2.1 ± 0.1b
Liver triglyceride content (mg/g) 9.4 ± 1.7 74.8 ± 6.2 2.4 ± 0.2b 27.7 ± 6.2b
Plasma cholesterol (mg/dl) 87 ± 4 107 ± 7 35 ± 4b 63 ± 3b
Plasma triglycerides (mg/dl) 129 ± 24 90 ± 13 24 ± 3b 60 ± 7
Plasma FAs (M) 366 ± 35 984 ± 84 148 ± 11b 1055 ± 149
Plasma insulin (ng/ml) 1.3 ± 0.12 0.14 ± 0.02 1.1 ± 0.16 0.14 ± 0.02
Blood glucose (mg/dl) 114 ± 5 58 ± 5 113 ± 4 57 ± 3
Male mice (12–14 weeks, four per group) were injected intraperitoneally four times with polyI:polyC and then studied 28 days after the last injection. The nonfasted
groups were fed a chow diet ad libitum prior to study. The fasted groups were fasted 12 hr prior to study. Food was removed from the cages at 9 p.m., which is 1 hr
before the beginning of the dark cycle. Each value represents mean ± SEM of four values. Asterisks denote level of statistical significance (Student’s t test) between
wild-type and L-Scap− mice in the nonfasted and fasted states.
a p < 0.05
b p < 0.01fasted L-Scap mice, and it declined to normal when the mice FA production (Horton et al., 2002). The data suggest that the
Figure 4. Relative amounts of various mRNAs in
epididymal fat pads from wild-type and L-Scap−
mice after 12 hr of fasting
Mice used here are the same as those in Table 3.
Total RNA from four mice in each group (N, non-
fasted; F, fasted) was pooled and quantified by real-
time PCR as described in Experimental procedures.
Each value represents the amount of mRNA relative
to that in the nonfasted wild-type mice, which is ar-
bitrarily defined as 1. IRS, insulin receptor substrate;
Glut, glucose transporter; PEPCK, phosphoenol
pyruvate carboxykinase.(Figure 4). The mRNA for SREBP-2, which is not affected by
insulin, showed no change. SREBP-1c target gene mRNAs
also declined. The declining mRNAs include acetyl-CoA car-
boxylase and fatty acid synthase, two transcripts whose en-
coded proteins are most directly concerned with FA synthesis.
There was an even more dramatic decline in mRNAs encoding
enzymes that supply the acetyl-CoA substrate for FA synthe-
sis, namely ATP-citrate lyase and acetyl-CoA synthetase. The
transcript for long-chain fatty acyl elongase (LCE), an SREBP
target that extends FA chain lengths (Moon et al., 2001), also
declined. Somewhat surprisingly, there was no decline in stea-
royl-CoA desaturase-1, a gene that is controlled dually by
SREBPs and by liver X receptors (Liang et al., 2002). The
mRNAs for two crucial enzymes of cholesterol biosynthesis,
HMG CoA synthase and HMG CoA reductase, did not decline
with fasting, a finding consistent with the previous conclusion
that these genes respond primarily to SREBP-2 (Horton et al.,
2002). The mRNAs encoding genes in the insulin signaling
pathway were not altered in L-Scap− mice, and they changed
only minimally with fasting. The mRNA for IRS-2, which was
previously shown to be downregulated by insulin in hepato-
cytes (Shimomura et al., 2000), rose as expected with fasting,
but it was no different in the wild-type and L-Scap− animals.
Consistent with an increased insulin sensitivity in the adipose
tissue of L-Scap− mice, the mRNA for Glut-4, the insulin-regu-
lated mediator of glucose uptake, was elevated in the non-
−48were fasted. PEPCK, a gene that is also suppressed by insulin
(O’Brien and Granner, 1996), rose to the same extent in wild-
type and L-Scap− mice upon fasting. Considered together, the
data in Table 3 and Figure 4 are consistent with the notion that
the increases in lipogenic mRNAs in adipose tissue of the
chow-fed L-Scap− mice are the result of an increase in insulin
sensitivity, which in turn increases SREBP-1c mRNA.
Discussion
The data in this paper reveal a previously unsuspected adap-
tive response to a selective reduction in FA synthesis in mouse
liver. When hepatic FA synthesis is severely reduced as a result
of SCAP deficiency in liver, nonhepatic tissues compensate on
a molecule-for-molecule basis so that total body FA synthesis
remains nearly unchanged. The studies in epididymal fat pad
indicate that white adipose tissue accounts for the increase in
extrahepatic fatty acid synthesis seen in the whole carcass.
This conclusion was supported by an additional experiment
with 3H2O in which we demonstrated a 3.5-fold increase in
fatty acid synthesis in epididymal fat pads but no detectable
increase in skeletal muscle of the L-Scap− mice. We also ob-
served no increase in heart or kidney (data not shown).
The increase in fatty acid synthesis in adipose tissue of
L-Scap− mice is mediated by an increase in SREBP-1c, a tran-
scription factor that activates all of the genes necessary forCELL METABOLISM : JANUARY 2005
Fat metabolism in L-Scap− miceupregulation of adipocyte SREBP-1c is mediated by insulin, as
indicated by the observation that the compensatory response
is abrogated when L-Scap− mice are fasted and insulin levels
decline. The compensatory increase in adipocyte FA synthesis
maintains much of the adipose tissue mass, even when the
animals are placed on a fat-free, high-carbohydrate diet for
several weeks.
Although the increase in adipocyte SREBP-1c appeared to
be caused by insulin, we did not find elevated insulin levels in
L-Scap− mice. If anything, plasma insulin tended to be slightly
reduced in L-Scap− animals (Tables 1 and 3 and Figure 3). Dur-
ing the glucose tolerance test, we observed reduced plasma
glucose in L-Scap− mice without any elevation in plasma insu-
lin (Figures 3A and 3B), suggesting that some tissues in these
mice were hypersensitive to insulin. This hypersensitivity was
manifested in adipose tissue by the increased level of phos-
pho-Akt and the enhanced uptake of [3H]2-deoxyglucose (Fig-
ures 3D–3F). The enhanced [3H]2-deoxyglucose uptake was
consistent with the 2.5-fold increase in mRNA encoding
Glut-4, an insulin-responsive gene in this tissue (Figure 4).
There was a slight increase in [3H]2-deoxyglucose uptake in
skeletal muscle of L-Scap− mice, but it was not statistically
significant. This may indicate a slight degree of increased insu-
lin sensitivity in muscle, although we did not detect an increase
of phosphorylated Akt in this tissue (Figure 3F). Further studies
to define the level of insulin sensitivity in different organs will
require hyperinsulinemic euglycemic clamps.
The mechanism for the increase in adipocyte insulin sensitiv-
ity in L-Scap− mice is not known. A clue emerges from the
observation that the upregulation of adipocyte SREBP-1c and
its target mRNAs did not occur immediately after hepatic SCAP
levels were reduced in the L-Scap− mice. In adipose tissue,
the mRNA levels were normal 5 days after the last polyI:polyC
injection, even though hepatic mRNAs for the FA biosynthetic
genes had already declined by the maximal amount (Figure
1B). Thereafter, in adipocytes, the target mRNA levels rose in
concert with the rise in SREBP-1c mRNA. These findings raise
the possibility that insulin sensitivity in adipose tissue does not
increase until a regulatory molecule (possibly a free or esteri-
fied FA) has been depleted from this tissue. With this possibility
in mind, we attempted to reverse the increase in lipogenic
mRNAs in adipose tissue of L-Scap− mice by feeding the ani-
mals three types of high-fat diets (20% lard, 20% olive oil, or
20% safflower oil for 15 days) or by intravenous injection of
VLDL-enriched plasma isolated from LDL receptor knockout
mice harboring a transgene for SREBP-1a (Horton et al., 1999).
Neither of these treatments suppressed the elevated lipogenic
mRNAs (data not shown). These negative results may have re-
sulted from a failure to deliver the necessary FA to adipose
tissue in adequate amounts. They do not in themselves ex-
clude the possibility that the enhanced adipocyte insulin sensi-
tivity results from a FA deficiency. This possibility is rendered
less likely by the observation that adipose tissue of L-Scap−
mice showed a normal FA composition compared to wild-type
mice (46% versus 48% oleate, 20% versus 18% palmitate,
18.2% versus 20.4% linoleate, 6.9% versus 5.0% palmitoleate,
and 3.0% versus 3.1% stearate, as determined by gas-liquid
chromatography of lipids extracted from adipose tissue of
L-Scap− mice on a chow diet). Moreover, the level of lipopro-
tein lipase (LPL) mRNA is normal in adipose tissue of these
mice (Figure 1A), and these animals are presumably able to
take up polyunsaturated FAs from circulating VLDL, which is
reduced but not absent. The finding of enhanced insulin re-CELL METABOLISM : JANUARY 2005sponsiveness despite normal polyunsaturated FA levels argues
against the hypothesis that the increase in adipocyte SREBP-
1c activity is attributable to a gross deficiency of polyunsatu-
rated FAs.
Despite the 70%–80% reduction in SCAP mRNA in liver and
the consequent reduction in mRNAs derived from the SREBP
target genes, livers of L-Scap− mice were nevertheless able to
increase the mRNAs for fatty acid biosynthetic enzymes when
placed chronically on a fat-free diet (Table 2), and this was as-
sociated with an increase in hepatic FA synthesis from 3H2O
(Figure 2). This upregulation is the result of the increase in he-
patic SREBP-1c mRNA in liver (see Table 2). The increase in
SREBP target gene mRNAs implies that some of this SREBP-
1c is processed to the nuclear form. This processing is pre-
sumably due to the residual 20%–30% of SCAP that remains
in the liver after Cre-mediated recombination. It might also be
due to ChREBP, a transcription factor that is activated by glu-
cose in liver and stimulates FA-synthesizing genes in a SREBP-
independent manner (Iizuka et al., 2004). Even though the
SREBP target mRNAs increased in the liver of the L-Scap−
mice on the chronic fat-free diet, they all still remained mark-
edly below normal values (Table 2), implying that the process-
ing of SREBP-1c was inefficient.
The current results resemble in some ways the observations
in LO-MCK mice, another model of triglyceride-deficient adipo-
cytes (Weinstock et al., 1997; Levak-Frank et al., 1997; Wagner
et al., 2004). These animals lack both copies of the gene en-
coding LPL, the enzyme that allows entry of lipoprotein-derived
FAs into adipose tissue and muscle. To prevent the lethal ef-
fects of muscle LPL deficiency, LO-MCK mice carry a transgene
encoding LPL under control of the muscle creatinine kinase
promoter, which gives high-level expression in muscle but not
in fat. These animals were observed to overproduce FAs in adi-
pose tissue (Weinstock et al., 1997). This was attributed to an
increase in adipocyte SREBP-1c, which was in turn attributed
to the high level of circulating insulin in these mice (Wagner et
al., 2004). The hyperinsulinemia was associated with hypergly-
cemia and muscle insulin resistance, which was attributed to
the increased uptake of FAs into muscle, owing to LPL overex-
pression in this tissue (Kim et al., 2001).
As discussed above, L-Scap− mice are not insulin resistant.
Moreover, in contrast to LO-MCK mice, which showed a defi-
ciency of polyunsaturated FAs in adipose tissue triglycerides,
L-Scap− mice do not have such a deficiency. Despite the differ-
ences in insulin sensitivity, L-Scap− mice share with LO-MCK
mice an important feature, namely an 80% reduction in VLDL
triglycerides. In LO-MCK mice, this reduction was attributed to
enhanced uptake of VLDL triglycerides in muscles that overex-
press LPL (Levak-Frank et al., 1997). In L-Scap− mice, the de-
cline is likely due to a reduced output of VLDL by the liver,
owing to the reduction in hepatic FA synthesis. Both animal
models also share a significant reduction in plasma HDL-cho-
lesterol. In LO-MCK mice, this reduction was shown to be
caused by an increased catabolism of HDL-cholesteryl esters
(Levak-Frank et al., 1997). The fall in HDL-cholesterol is more
profound in L-Scap− mice, but the mechanism has not yet
been investigated.
The reduction in VLDL triglycerides in L-Scap− mice il-
lustrates the potential advantage to an animal that synthesizes
its FAs in adipose tissue rather than liver. In humans, such a
reduction in VLDL triglycerides would be expected to lead to a
marked reduction in plasma LDL, since most LDL is derived
from VLDL. LDL levels in humans are much higher than those49
A R T I C L Ein mice because humans clear LDL inefficiently from plasma,
owing to a relative deficiency of hepatic LDL receptors (Brown
and Goldstein, 1983; Horton et al., 1999). If hepatic FA synthe-
sis could be inhibited selectively in humans and if adipose tis-
sue responded by a compensatory upregulation as in mice,
human LDL levels would be expected to fall dramatically.
Moreover, the decrease in VLDL itself might help to relieve the
insulin resistance that occurs in humans with the metabolic
syndrome and would be predicted to lead to a reduction in
atherosclerosis and diabetes. Whether humans would also
show a reduction in HDL and whether this would have a nega-
tive effect on atherosclerosis cannot be predicted. Existing
data on L-Scap− mice raise the possibility, at least, that an in-
hibitor of hepatic SCAP activity might have beneficial effects
in humans.
Experimental procedures
Materials and general methods
Blood was drawn from the retroorbital sinus after administration of halo-
thane anesthesia; the plasma was separated immediately and stored at
−70°C. Concentrations of plasma and liver cholesterol and triglycerides and
of plasma insulin and free FAs were measured as described (Engelking et
al., 2004). Blood glucose was measured with Glucometer Elite (Bayer
Corp.), and plasma leptin was measured with a mouse leptin RIA kit from
Linco (Cat. No. ML-82K). We obtained polyI:polyC from Sigma-Aldrich (Cat.
No. P0913) and 2-deoxy-D-[1-3H]glucose from Amersham Pharmacia (Cat.
No. TRK383). Body fat content in mice was measured by nuclear magnetic
resonance (NMR) using a Bruker Minispec mq7.5 NMR analyzer (Bruker
Optics) as described by Cui et al. (2004)
Animal treatments
All mice were housed in colony cages with a 12 hr light/12 hr dark cycle
and fed a standard chow diet containing 6% fat (Teklad Mouse/Rat Diet
7002 from Harlan Teklad Premier Laboratory Diets). A fat-free diet (Cat. No.
960238) was purchased from ICN Biomedicals. L-Scap− mice (previously
referred to as Scapf/f;MX1-Cre mice) were generated as described (Matsuda
et al., 2001). The conditional deletion of the Scap gene in the liver was
induced by intraperitoneal injection of polyI:polyC (Kuhn et al., 1995). For
all studies, each mouse (wild-type and L-Scap−) received four injections of
300 l of a 1 mg/ml solution of polyI:polyC in water repeated every 48 hr
for four cycles. All mice, irrespective of diet, were sacrificed at the end of
the dark cycle. Albumin-Cre mice (B6.Cg-Tg[Alb-cre]21Mgn/J) were ob-
tained from the Jackson Laboratory (Stock #003574). All animal experi-
ments were performed with the approval of the Institutional Animal Care
and Research Advisory Committee of the University of Texas Southwestern
Medical Center.
Real-time PCR
Total RNA was prepared from mouse tissues using an RNA STAT-60 kit from
TEL-TEST “B” (Friendswood, TX). Equal amounts of RNA from four or five
mice were pooled and subjected to quantitative real-time PCR as previously
described (Liang et al., 2002). Primer sequences not previously described
are listed in Supplemental Table S1. All reactions were done in triplicate,
and the relative amounts of mRNAs were calculated using the comparative
CT method. Mouse cyclophilin mRNA was used as the invariant control.
Synthesis of cholesterol and FAs in vivo
Thirty-one days after the final polyI:polyC injection, each mouse was in-
jected intraperitoneally with 3H-labeled water (50 mCi in 0.25 ml of isotonic
saline), and 30 min later the liver and epididymal fat pads were removed for
measurement of 3H-labeled FAs and digitonin-precipitable sterols as pre-
viously described (Shimano et al., 1996). The remainder of the carcass was
placed in a 400 ml beaker; 250 ml of 6.7% KOH in ethanol was added, and
the beaker was placed in a water bath at 65°C for 8 hr, which was sufficient
time to dissolve the carcass. The dissolved carcass was filtered through
gauze, and the filtrate volume was adjusted to exactly 100 ml with ethanol.
An aliquot (5 ml) was removed and extracted by the method previously50described (Shimano et al., 1996). The rates of cholesterol and FA synthesis
were calculated as micromoles of 3H-radioactivity incorporated into FAs or
digitonin-precipitable sterols per hr per gram of tissue or per whole organ
or carcass.
Tissue uptake of [3H]2-deoxyglucose
Twenty-four days after the final injection of polyI:polyC, mice were fasted
for 16 hr, after which each mouse was injected intraperitoneally with
2-deoxy-D-[1-3H]glucose (0.5 Ci/g body weight) mixed with 20% (w/v)
D-glucose (2 mg/g body weight). Tissue uptake of [3H]2-deoxyglucose and
its calculation were carried out as described by Zisman et al. (2000).
Glucose and insulin tolerance tests
Eighteen days after the final polyI:polyC injection, the mice were fasted for
16 hr and injected intraperitoneally with 20% D-glucose (2 mg/g body
weight). Twenty days after the final polyI:polyC injection, nonfasted mice
were injected intraperitoneally 4 hr after beginning of the light cycle with
0.25 U/kg body weight of human insulin (Eli Lilly). Blood samples for glu-
cose measurement were obtained from the tail vein at the indicated time.
Immunoblot analysis of Akt in tissues
Whole-cell lysates of liver were prepared as previously described (Shimo-
mura et al., 2000). Whole-cell lysates of epididymal fat and skeletal muscle
were prepared as follows: w200 mg of tissue was homogenized in 1.5 ml
of ice-cold lysis buffer containing 0.1% (w/v) SDS, 0.1% (w/v) sodium de-
oxycholate, 1% (w/v) Triton X-100, 50 mM Tris-HCl (pH 7.6), 5 mM sodium
EDTA, 150 mM NaCl, 5 units/ml DNase I (Ambion, Cat. No. 2222), 1× prote-
ase inhibitor cocktail (Sigma-Aldrich, Cat. No. P8340), and 1× phosphatase
inhibitor cocktails 1 and 2 (Sigma-Aldrich, Cat. No. P2850 and P5726). The
homogenate was kept on ice for another 30 min. After centrifugation at
3000 × g for 10 min at 4°C, the floating fat layer was removed, the superna-
tant was transferred to a new tube, and an aliquot was removed for protein
measurement using a BCA kit (Pierce). To the remaining extract, 4× SDS
loading buffer (12% SDS, 0.02% [w/v] bromophenol blue, 30% [v/v] glyc-
erol, 0.15 mM Tris-HCl [pH 6.8], and 6% [v/v] β-mercaptoethanol) was
added to a final concentration of 1×.
Aliquots of whole-cell lysates from liver (50 µg), fat pads (50 µg), and
muscle (100 µg) were subjected to SDS-PAGE on 10% gels followed by
immunoblot analysis (Shimomura et al., 2000) with a 1:1000 dilution of anti-
Akt or anti-phospho-Akt(Ser473) (Cell Signaling, Cat. No. 9272 and 9271).
Supplemental data
Supplemental data include one table and Supplemental References and
can be found with this article online at http://www.cellmetabolism.org/cgi/
content/full/1/1/41/DC1/.
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